BioSapien

BioSapien is an early clinical-stage biotech company developing MediChip™, a localized drug delivery platform. This groundbreaking technology is surgically attached to a site of interest, enabling sustained and localized release of therapeutic agents over a period of 30 days. The first clinical indication Biosapien is pursuing with MediChip will be colorectal cancer; locally delivering 5-FU, a well-established standard-of-care therapy. Through biphasic drug release to the tumor site, BioSapien seeks to improve outcomes for patients. We believe MediChip™ can serve as a novel therapeutic tool that complements existing treatments through localized drug delivery.